申请人:Eli Lilly and Company
公开号:US04018923A1
公开(公告)日:1977-04-19
A method of treating inflammation which utilizes topically-active 5,6-diaryl-1,2,4-triazines having the formula, ##STR1## wherein R is hydrogen or --(X).sub.n R.sub.1, in which X is either O or S, n is an integer which is either 0 or 1, and R.sub.1 is C.sub.1 -C.sub.8 alkyl, C.sub.7 -C.sub.8 aralkyl, C.sub.3 -C.sub.8 cycloalkyl, or C.sub.4 -C.sub.8 (cycloalkyl)alkyl; and R.sub.2 and R.sub.3 independently are halo, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy, or di(C.sub.1 -C.sub.3 alkyl)amino, with the proviso that at least one of R.sub.2 and R.sub.3 is halo or C.sub.1 -C.sub.3 alkyl; and the pharmaceutically-acceptable acid addition salts of basic members thereof.
一种治疗炎症的方法,利用具有以下化学式的局部活性的5,6-二芳基-1,2,4-三嗪:其中R为氢或--(X).sub.n R.sub.1,其中X为O或S,n为0或1的整数,R.sub.1为C.sub.1 -C.sub.8烷基,C.sub.7 -C.sub.8芳基烷基,C.sub.3 -C.sub.8环烷基,或C.sub.4 -C.sub.8(环烷基)烷基;R.sub.2和R.sub.3独立地为卤素、C.sub.1 -C.sub.3烷基、C.sub.1 -C.sub.3烷氧基或二(C.sub.1 -C.sub.3烷基)氨基,但R.sub.2和R.sub.3中至少有一个为卤素或C.sub.1 -C.sub.3烷基;以及其药学上可接受的酸盐。